Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis

doi:10.4254/wjh.v10.i10.662

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7718)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

453

WORD

176

HTML

4571

Figures (1-1)

246

Tables (1-2)

239

Sum=5685

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

858

Download

1175

Sum=2033

Oct 27, 2018 (publication date) through Jan 11, 2025

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Oct 27, 2018; 10(10): 662-669
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.662

Table 2 Complement regulators

Type of regulators	Regulators	Functions
Complement regulatory protein	DAF/CD55, Crry, FH, FI	Inhibit C3, C5 convertase
Complement regulatory protein	CD59, protein S, clusterin	Inhibit MAC
Complement inhibitor	C1-INH	Inhibit C1r, C1s
Targeted inhibitor	h5G1, 1-ScFv	Inhibit C5 activation
RNA aptamer	Specifically bind C1q, C5

DAF: Decay accelerating factor; Crry: Complement receptor 1-related protein y; FH: Factor H; FI: Factor I; MAC: Membrane attack complex.

Citation: Lin CJ, Hu ZG, Yuan GD, Lei B, He SQ. Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis. World J Hepatol 2018; 10(10): 662-669
URL: https://www.wjgnet.com/1948-5182/full/v10/i10/662.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i10.662